SCHEMBL1379532

SCHEMBL1379532

O=[N+]([O-])c1ccc(Cl)c2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.61
CTSB P07858 4/20 0.60
ALDH1A1 P00352 4/20 0.59
CYP1A2 P05177 1/20 0.54
CYP2A6 P11509 1/20 0.54
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
AR P10275 1/20 0.50
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
GAA P10253 1/20 0.47
VCAM1 P19320 3/20 0.46
HPRT1 P00492 1/20 0.46
HPGD P15428 1/20 0.46
CYP3A4 P08684 1/20 0.46
ALOX15 P16050 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3193192 0.88 TDP1 (0.75) TDP1CTSBALDH1A1CYP1A2CYP2A6
SCHEMBL7788656 0.87 TDP1 (0.80) TDP1CTSBALDH1A1KDM4EMEN1
SCHEMBL18810941 0.81 ALDH1A1 (0.52) TDP1ALDH1A1CYP1A2CYP2A6KDM4E
SCHEMBL9078242 0.80 TDP1 (0.57) TDP1CTSBALDH1A1KDM4EMEN1
SCHEMBL4871313 0.79 TDP1 (0.61) TDP1CTSBALDH1A1KDM4EMEN1
SCHEMBL57166 0.77 TDP1 (1.00) TDP1CTSBALDH1A1TSHRGAA
SCHEMBL29475175 0.77 TDP1 (1.00) TDP1CTSBALDH1A1TSHRGAA
SCHEMBL15302617 0.76 TDP1 (0.50) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL5071420 0.76 TDP1 (0.57) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL619318 0.76 MAPT (0.52) TDP1ALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025043967-A1 PREPARATION METHOD FOR AND USE OF NANOPOROUS CARBON MATERIAL HAVING CONTINUOUS STRUCTURE 东南大学 2025-03-06 WO claimed
CN-118515261-A Preparation method of nano porous carbon material with continuous structure and application of nano porous carbon material as heat insulation material 东南大学 2024-08-20 CN claimed
CN-117088357-A Preparation method and application of nano porous carbon material with continuous structure 东南大学 2023-11-21 CN claimed
CN-116925498-A High-pressure-bearing branched epoxy resin plugging material and oil-based drilling fluid 西南石油大学 2023-10-24 CN claimed
JP-4731114-B2 2011-07-20 JP claimed
US-20100222330-A1 New Compounds BIOVITRUM AB (SE) 2010-09-02 US claimed
US-7572787-B2 Substituted naphthalene sulfonamides BIOVITRUM AB (SE) 2009-08-11 US claimed
CN-100410256-C Optical diamine monomer containing di-dehydrated-hexitol unit and process for preparing same UNIV TSINGHUA (CN) 2008-08-13 CN claimed
CN-1320031-C Polyamide containing isosorbide unit and process for preparing same UNIV TSINGHUA (CN) 2007-06-06 CN claimed
US-20070066598-A1 Compounds BIOVITRUM AB, A SWEDEN CORPORATION 2007-03-22 US claimed
US-20070066600-A1 Compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2007-03-22 US claimed
CN-1800185-A Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes. BIOVITRUM AB (SE) 2006-07-12 CN claimed
CN-1702097-A Optical polyimide containing isosorbide unit and process for preparing same UNIV TSINGHUA (CN) 2005-11-30 CN claimed
CN-1702095-A Polyamide containing isosorbide unit and process for preparing same UNIV TSINGHUA (CN) 2005-11-30 CN claimed
CN-1702071-A Optical diamine monomer containing di-dehydrated-hexitol unit and process for preparing same UNIV TSINGHUA (CN) 2005-11-30 CN claimed
CN-1522245-A Substituted sulfonamide compounds, process for their preparation and their use as medicaments for the treatment of CNS disorders, obesity and type II diabetes �Ȱ�ά����ķ�ɷݹ�˾ 2004-08-18 CN claimed
EP-1412325-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2004-04-28 EP claimed
US-20030158202-A1 Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders PROXIMAGEN NEUROSCIENCE PLC (GB) 2003-08-21 US claimed
WO-2002100822-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2002-12-19 WO claimed
US-4375550-A Hydrogenation of halogen-substituted aromatic nitro compounds JOHNSON, MATTHEY & CO., LIMITED (GB) 1983-03-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066598-A1 Compounds SULT2A1, STS, SLC5A2 TDP1 4117/4885CTSB 1626/4885ALDH1A1 262/4885
US-20030158202-A1 Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders SULT2A1, SULT1A1, SULT1E1 TDP1 2654/4885CTSB 3013/4885ALDH1A1 401/4885
US-20070066600-A1 Compounds SULT2A1, STS, SLC5A2 TDP1 4117/4885CTSB 1626/4885ALDH1A1 262/4885
US-20100222330-A1 New Compounds SULT2A1, GPR119, STS TDP1 4016/4885CTSB 1810/4885ALDH1A1 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.